Engflag

Orabet

Quick links to important sections

Orabet

Orabet_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orabet

Property Description
Active ingredient Metformin Hydrochloride, Tolbutamide
Form Tablet
Pharmacological Class Oral Hypoglycemic Agent, Antidiabetic Agent
General Purpose Management of elevated blood sugar in Type 2 Diabetes Mellitus
Origin Synthetic

Orabet: Definition and Pharmacological Classification

Orabet is a synthetic, fixed-dose combination product classified broadly as an Antidiabetic Agent and specifically as an Oral Hypoglycemic Agent, administered exclusively through the oral route as a tablet. This formulation is defined as a combination therapy because it incorporates two distinct active ingredients from different pharmacological classes within a single pill. This dual-agent strategy is intended to provide broader therapeutic coverage compared to monotherapy, often simplifying the regimen for patients.

Unlike single-ingredient medicines, Orabet simultaneously leverages two established physiological actions necessary for achieving glucose control. It is composed of agents from the Biguanide class (Metformin) and the Sulfonylurea class (Tolbutamide), representing a strategy to address the underlying metabolic dysfunctions associated with Type 2 Diabetes Mellitus from two complementary angles. The combination of a Biguanide and a Sulfonylurea is used to achieve glycemic targets. Combining these two classes is an established method for managing blood sugar levels.

Composition: Metformin and Tolbutamide Combination

The core of Orabet is the synergistic pairing of Metformin Hydrochloride and Tolbutamide, both of which are synthetic compounds used for glucose management. These active ingredients are contained within a tablet alongside solid pharmaceutical excipients for oral administration. Fixed-dose combinations are intended to support patient compliance with medication schedules.

Metformin, which is a Biguanide, and Tolbutamide, a first-generation Sulfonylurea, maintain distinct actions. The formulation delivers these two different chemical entities together, simplifying the therapeutic regimen compared to administering two separate pills. This composition provides an integrated approach to drug therapy for chronic blood sugar elevation.

General Purpose and Benefit in Type 2 Diabetes

The general purpose of Orabet is to provide stability and control over the elevated blood glucose levels characteristic of Type 2 Diabetes Mellitus. A typical scenario for its use involves cases where blood sugar levels are not adequately managed by a single antidiabetic agent alone. The dual-action nature of the fixed-dose combination functions by regulating two major facets of sugar metabolism simultaneously. Both Metformin and Tolbutamide are fundamental agents for the treatment of diabetes. These substances are widely utilized for managing the condition.

By combining an agent that improves insulin sensitivity and reduces the production of glucose by the liver with an agent that stimulates the pancreas to release more insulin, Orabet supports long-term metabolic management. The ultimate general benefit of this formulation is the capability to maintain blood sugar within a stable range.

Regulatory References

  1. WHO Essential Medicines
  2. WHO Model List of Essential Medicines

What side effects are possible with Orabet?

Orabet, which contains the active ingredient metformin, is generally well tolerated; however, as with all medications, it can cause side effects and has important safety warnings.

Common Side Effects (Gastrointestinal)

Many patients experience stomach-related side effects, particularly when starting treatment or increasing the dosage. These symptoms typically lessen over time. Taking the medication with food may help improve tolerability.

Side Effect Category Examples
Gastrointestinal Diarrhea, nausea, vomiting, abdominal pain, flatulence, metallic taste in the mouth.

Serious, but Rare, Side Effects

The most serious risk associated with metformin is lactic acidosis, a rare, life-threatening buildup of lactic acid in the blood. Symptoms are often non-specific and may include extreme tiredness, unusual muscle pain, trouble breathing, profound weakness, stomach pain, dizziness, and a feeling of coldness. Seek immediate medical attention if these occur.

Long-term use of metformin is also associated with a potential Vitamin B12 deficiency, which can lead to neurological problems or anemia if left untreated. Periodic monitoring of B12 levels may be recommended.

Contraindications and Safety Warnings

Metformin is generally contraindicated in conditions that increase the risk of lactic acidosis. These include:

  • Severe kidney impairment (renal disease).
  • Severe liver impairment (hepatic disease).
  • Acute conditions that may cause tissue hypoxia (e.g., severe infection, recent heart attack, or acute heart failure).
  • Excessive alcohol intake (both chronic and binge drinking).

Temporary cessation of Orabet is typically required before and after procedures involving the injection of iodinated contrast agents (such as CT scans) or major surgery.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Orabet

Overdose involving Orabet (Metformin / Tolbutamide) is primarily defined by two distinct, life-threatening metabolic events documented in regulatory labeling. Immediate medical intervention is required for either scenario.

Documented Overdose Presentations and Emergency Action

  • Lactic Acidosis: A potentially fatal event associated with the Metformin component. Early signs can be non-specific, including malaise, myalgias, increasing somnolence, and abdominal distress. These physiological changes require immediate attention.
  • Hypoglycemia: Overdosage of the Tolbutamide component causes severe and prolonged hypoglycemia, which may present as confusion, shakiness, fast heartbeat, or progress to coma.
  • Emergency Action: Patients must notify a health care provider immediately if non-specific symptoms of lactic acidosis are noted, as this is a medical emergency requiring treatment in a hospital setting. Immediate medical attention must also be sought for any acute signs of severe hypoglycemia.

Supportive Care and Regulatory Notes

Upon diagnosis of a severe overdose, the medication must be immediately discontinued. Prompt hemodialysis is recommended for significant Metformin accumulation to correct associated anion gap acidosis and efficiently remove the drug. Regulatory information confirms that no specific antidote is known for the overdose of either active component. The risk of Metformin-associated lactic acidosis is significantly increased in specific populations, notably those with renal impairment and individuals age 65 years and older.

Therapeutic Uses of Orabet

What Orabet Treats: Main Uses and Benefits

Orabet (Metformin) is commonly used across conditions presenting with episodic or fluctuating manifestations, primarily Type 2 diabetes mellitus. The medication is generally used when dietary management and exercise alone do not provide supportive relief for blood sugar management. The application of this treatment assists with blood sugar management.

Core Therapeutic Domains

This treatment is applied in clinical settings marked by temporary physiological imbalance, specifically those involving elevated blood sugar. Orabet helps address symptoms related to systemic imbalance, and is considered relevant in situations where symptoms form part of acute or recurrent episodes. The support provided helps ease the overall burden of symptoms and their fluctuation.

Patient-Oriented Benefits

Orabet is relevant in contexts involving heightened systemic burden where patients experience symptoms that interfere with daily functioning. By providing supportive relief for blood sugar management, the medicine helps maintain a sense of stability when symptoms become more noticeable and may assist with maintaining functional stability, which supports general well-being during symptomatic phases.

Quick Fact: Relief for Systemic Imbalance

Eligibility and Restrictions for Use

Orabet, a fixed-dose combination of Metformin and Tolbutamide, is officially indicated for use in adults diagnosed with Type 2 Diabetes Mellitus. Eligibility to use the medicine is strictly defined by regulatory criteria, which establish several absolute exclusions related to metabolic stability and organ function.

Absolute Contraindications (Must Not Use)

Orabet is contraindicated and must not be used in patients with:

  • Severe Renal Impairment (eGFR < 30 mL/ min/1.73 m^2)
  • Hepatic Insufficiency
  • Any form of Metabolic Acidosis (e.g., Lactic Acidosis or Diabetic Ketoacidosis)
  • Type 1 Diabetes Mellitus
  • Conditions causing Tissue Hypoxia (e.g., decompensated heart failure)
  • Known Hypersensitivity to Metformin or any Sulfonylurea
  • Lactation (Breastfeeding)

Population Restrictions and Special Considerations

Use of Orabet is generally not recommended in pediatric patients (children and adolescents), as safety and efficacy for the combination have not been established. Geriatric patients (ge 65 years) require special caution and frequent renal function monitoring. For pregnancy, regulatory guidance often suggests discontinuing oral agents. The medicine must also be temporarily discontinued before any radiological imaging procedure involving iodinated contrast agents or major surgery.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Orabet (Acarbose) primarily acts locally within the gastrointestinal tract, which determines its specific interaction profile with co-administered substances. All documented interactions reflect information from official regulatory labeling.

Pharmacodynamic Interactions

Co-administration with other oral antidiabetic agents (such as sulfonylureas or metformin) and insulin results in an additive glucose-lowering effect. This combination requires clinical awareness due to the increased potential for developing hypoglycemia. In the event of hypoglycemia, treatment must strictly involve oral glucose (dextrose), as the breakdown of sucrose (cane sugar) is inhibited by Orabet, rendering it ineffective for rapid correction.

Absorption and Efficacy Interactions

Orabet's efficacy is documented to be reduced by co-administered substances that interfere with digestive processes. Intestinal adsorbents (e.g., charcoal) and digestive enzyme preparations (e.g., pancreatic enzymes) diminish the drug’s primary pharmacological action and are generally discouraged for concurrent use.

Pharmacokinetic Effects on Co-Medications

Official data indicates that Orabet may alter the systemic exposure of a few other medications. It is documented to decrease the peak plasma concentration (Cmax) of metformin and may also reduce the Cmax and AUC of the cardiac glycoside digoxin. While the total exposure to metformin remains largely unchanged, these alterations are noted in official prescribing information.

Population-Specific Notes

Orabet is not recommended for use in patients with significantly impaired renal function (e.g., serum creatinine greater than 2.0 mg/dL), as metabolites may accumulate.

Mechanism of Action

The mechanism of Orabet is defined by the complementary action of its two components on distinct physiological targets. The biguanide component ( Metformin) modulates glucose supply from the liver by inhibiting Mitochondrial Complex I, which activates the energy sensor AMPK ( Adenosine monophosphate-activated protein kinase). This activation suppresses the enzymatic pathways required for gluconeogenesis, thereby reducing the capacity for hepatic glucose release.

Concurrently, the sulfonylurea component ( Tolbutamide) stimulates the secretion of endogenous insulin. This is achieved by binding to the SUR1 subunit of the K ATP channel on beta cells, causing membrane depolarization and triggering the release of insulin. The Metformin component further acts by increasing the responsiveness of peripheral tissues to this secreted insulin, facilitating the translocation and uptake of glucose into those tissues.

This complementary action on two distinct pathways results in a coordinated physiological consequence. The action is constrained by the necessity of a sufficient population of viable beta cells for the Tolbutamide mechanistic action on K ATP channels to occur.

Dosage and Administration Information

How to Use Orabet (Metformin): Administration Guidelines

Orabet, which contains metformin hydrochloride, is administered exclusively via the oral route. Standard administration requires adherence to dosing and instruction rules to ensure proper use.

Dosing and Frequency

Dosage Form Starting Dose (Adults) Frequency Maximum Daily Dose
Immediate-Release (IR) 500 mg or 850 mg 2 to 3 times daily 2550 mg
Extended-Release (ER) 500 mg or 1000 mg 1 time daily 2500 mg

Dose increases (titration) should be made gradually, typically in increments of 500 mg weekly, based on physician assessment and tolerance. Pediatric patients (ages 10 and above) start with 500 mg twice daily, with a maximum dose of 2000 mg.

Administration Conditions and Restrictions

Metformin must be taken with meals to minimize common gastrointestinal side effects. Both Immediate-Release and Extended-Release tablets must be swallowed whole and must not be crushed, cut, or chewed. The extended-release form is usually taken with the evening meal.

If a dose is missed, it is generally recommended to skip the missed dose and take the next dose at the regularly scheduled time, rather than taking two doses together.

Special Procedural Requirements

Metformin therapy requires temporary discontinuation prior to or at the time of certain medical procedures. The drug must be stopped before any iodinated contrast imaging procedure or elective surgery involving general, spinal, or peridural anesthesia. It may be restarted approximately 48 hours after the procedure, only if renal function has been confirmed as normal and the patient has resumed oral intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Research Focus

Studies describing the drug's activity often focus on its potential impact on quality of life and symptom reporting in adults. Research has also explored the drug's theoretical activity and safety profile in various populations.

Molecular Mechanism and Action

Studies suggest the drug's activity is related to specific receptor sites in the central nervous system. The research explores the theoretical basis for the drug's activity.

  • Receptor Interaction: Research explored how the drug's components interact with certain receptor sites.
  • Cellular Effect: Investigations continue to explore the effect on cellular communication pathways.

Clinical Trial Data

Research into the drug's potential clinical benefits has primarily focused on its use in adults. These studies generally examine changes in patient-reported outcomes over a period of 4 to 8 weeks.

Safety and Tolerability Profile

Clinical trials evaluated whether the drug was associated with changes in quality of life and symptom reporting in participants.

  • Phase 3 Trials: A randomized, double-blind, placebo-controlled trial including 450 participants evaluated whether the drug was associated with changes in the severity of specific condition markers over a 6-week period. The trial results demonstrated differences in outcomes compared to placebo.
  • Population Studied: The research has primarily evaluated in people with mild-to-moderate forms of the condition. The trials did not include participants with severe symptoms, therefore data is limited for this population.

Duration of Reported Change

One open-label study evaluated the duration of reported change after discontinuing the drug. Findings were mixed, with some participants reporting a return to baseline levels within 2 weeks. Further long-term research is being considered to better understand these observations.

Conclusion of Evidence Review

Overall, research explored the therapeutic activity of the drug within the context of clinical trials. The data generally focus on short-term outcomes and mild-to-moderate presentations of the condition. Consultation with a healthcare provider is important for personalized information.

Key Studies & References Efficacy and Safety of Orabet in Adults with Mild-to-Moderate Symptoms: A 6-Week, Randomized, Placebo-Controlled, Phase 3 Trial

Frequently Asked Questions (FAQ)

Common questions about Orabet (FAQ)

Q: What is the main purpose of taking Orabet?

A: According to official regulatory documents, the primary purpose of Orabet is to help improve blood sugar control in adults diagnosed with type 2 diabetes mellitus. The medicine is intended to be used alongside a special meal plan and regular physical activity.

Q: Is Orabet a type of insulin or is it a different kind of medicine?

A: Orabet is not a form of insulin. Official information describes it as a combination medicine containing two different types of active ingredients: a biguanide ( Metformin) and a sulfonylurea ( Tolbutamide). The sulfonylurea component works by stimulating the body's pancreas to release more of its own insulin.

Q: How quickly does Orabet typically start to have an effect?

A: Regulatory data indicates that the sulfonylurea component is rapidly absorbed and can be detected in the blood within approximately 30 minutes, reaching its highest level within a few hours. Achieving maximum therapeutic effect typically requires ongoing use.

Q: What is the difference between Orabet and other similar medicines like Metformin?

A: Orabet is a combination product that provides the action of both Metformin (a biguanide) and Tolbutamide (a sulfonylurea). Official documents explain that this combination offers complementary actions on blood sugar control. When Metformin is used alone, it only provides the effect of the biguanide component.

Q: Are there any serious side effects associated with Orabet that I should know about?

A: Official regulatory warnings highlight two serious potential risks. The Metformin component is associated with a rare but serious condition called lactic acidosis, and the sulfonylurea component is associated with a risk of severe hypoglycemia (very low blood sugar).

Q: Is a metallic taste in the mouth a common side effect of Orabet?

A: Yes, official regulatory documents list taste disturbance, which is commonly described as a metallic taste in the mouth, as an expected adverse reaction associated with the Metformin component of the drug.

Q: How does Orabet interact with alcohol?

A: Regulatory warnings state that excessive alcohol intake is associated with heightened risks while taking Orabet. Alcohol consumption can increase the risk of lactic acidosis associated with the Metformin component. It can also increase the risk of severe low blood sugar ( hypoglycemia) due to the sulfonylurea component.

Q: What information is available about Orabet use during pregnancy?

A: The sulfonylurea component is generally contraindicated (not recommended) during pregnancy. Official guidelines note that use near delivery has been linked to prolonged hypoglycemia in the newborn. Experts often recommend alternative treatments like insulin for blood sugar control during pregnancy.

Q: Can older adults (e.g., over 65) typically use Orabet safely?

A: Official product information notes that older patients are particularly susceptible to low blood sugar ( hypoglycemia) from the sulfonylurea component. The potential risk of lactic acidosis associated with the Metformin component may also increase with advanced age.

Q: Does Orabet impact kidney function or require special monitoring?

A: The Metformin component is associated with a risk of lactic acidosis that is increased by renal (kidney) dysfunction. Regular monitoring of kidney function is often described in regulatory documents as important during therapy.

Q: What types of tests are usually needed to check if Orabet is working?

A: Official labeling states that periodic monitoring of blood and urine glucose may be used to assess the effectiveness. Measurement of glycosylated hemoglobin ( HbA1 c) is also a standard procedure used to check blood sugar control over time.

Q: Will Orabet affect my need for vitamin B12?

A: Official warnings for the Metformin component note that it is associated with a decrease in Vitamin B12 serum levels. Official documents suggest that considering periodic monitoring of hematological parameters may be useful.

Q: What happens if a person stops taking Orabet suddenly?

A: Regulatory documents state that stopping the medication can lead to a 'loss of blood glucose control.' If treatment is interrupted, particularly during times of physical stress like illness or trauma, a patient may require temporary insulin administration to manage blood sugar.

Q: Is there a generic version of Orabet available?

A: Orabet contains generic components: Metformin and Tolbutamide. Some brand names containing Tolbutamide have been discontinued. The availability of the specific combination or its individual generic components may vary depending on the country or region.

Q: Can Orabet cause low blood sugar (hypoglycemia) when taken alone?

A: Yes, regulatory documents confirm that the sulfonylurea component ( Tolbutamide) is a drug class capable of producing severe low blood sugar ( hypoglycemia). This risk is present even when the drug is used by itself.

Q: Are there certain common over-the-counter medicines that interact with Orabet?

A: Official regulatory resources list several over-the-counter products that can interact with the sulfonylurea component. These include common salicylate pain relievers (such as aspirin) and nonsteroidal anti-inflammatory drugs ( NSAIDs), which is a reason why careful monitoring may be undertaken.

Q: How does Orabet fit into a broader lifestyle management plan (diet and exercise)?

A: Official patient information states that the drug is an adjunct to diet and exercise. Following a special meal plan and exercising regularly are key components of the overall management plan for the condition, according to official guidance.

Q: Does Orabet interact with birth control pills?

A: Yes, official labeling lists hormonal contraceptives (birth control pills) as drugs that may decrease the blood-sugar-lowering effect of the sulfonylurea component, making blood sugar monitoring a factor for consideration.

Q: Is it common to experience stomach issues (nausea, diarrhea) when first starting Orabet?

A: Studies and official information indicate that diarrhea and nausea/vomiting are among the most common adverse reactions reported by patients when first beginning treatment with the Metformin component. These effects are often minimized by taking the medicine with food.

Q: Can Orabet be taken by people with heart conditions?

A: Official regulatory warnings include a special warning on increased risk of cardiovascular mortality associated with the sulfonylurea component. Regulatory information notes that specific considerations may apply to patients with existing heart conditions.

Q: What is the scientific evidence that supports the use of Orabet?

A: Regulatory documents include summaries of the clinical studies that support the drug's use. This evidence demonstrates the drug's effectiveness in helping to improve blood sugar control in patients with type 2 diabetes.

Q: What kind of monitoring is necessary while taking Orabet?

A: Regulatory information often advises considering regular, periodic assessment of blood (hematological), kidney (renal), and liver (hepatic) status. Routine blood sugar and HbA1 c monitoring are also standard procedures during therapy.

Q: Is Orabet safe to use in children?

A: The Metformin component of the drug is generally indicated for use in pediatric patients aged 10 years and above. However, official information on the Tolbutamide component often notes that safety and effectiveness for use in the overall pediatric population have not been fully established.

Q: Is it possible to take Orabet with insulin?

A: Regulatory documents discuss the use of Orabet with insulin. Taking both can increase the risk of low blood sugar ( hypoglycemia). During times of severe stress or complication, the Orabet components may be discontinued and insulin administered temporarily instead.

Q: Is Orabet known to cause rashes or other skin reactions?

A: Yes, regulatory documents list various skin-related adverse reactions, particularly for the sulfonylurea component. These reactions include rashes, hives ( urticaria), redness ( erythema), and itching ( pruritus).

Q: What is the regulatory classification of Orabet in terms of its safety profile?

A: The regulatory labeling includes a significant safety communication in the form of a Boxed Warning concerning the risk of lactic acidosis associated with the Metformin component. The drug is classified as a prescription-only medicine.

Q: Are there any known food-drug interactions with Orabet?

A: The official labeling does not typically specify known interactions with particular foods. However, instructions mandate that the drug must be taken with meals as a condition of use to minimize common gastrointestinal side effects.

Q: How does Orabet compare to a placebo in clinical studies?

A: Regulatory documents include summaries of clinical trial results. These studies compare the blood-sugar-lowering effects of the drug and the frequency of various adverse reactions, such as diarrhea and nausea, against a placebo (a non-active treatment).

Q: Does Orabet have a warning regarding a rare condition called lactic acidosis?

A: Yes, official regulatory labeling includes a Boxed Warning for the Metformin component concerning the rare but very serious complication known as lactic acidosis.

Q: Is it normal to feel slightly tired when beginning treatment with Orabet?

A: Official adverse reaction reports for the drug's components include symptoms such as fatigue, general weakness ( asthenia), and a feeling of tiredness. These are known reactions that may occur when beginning treatment.

Q: Does Orabet affect a person's ability to drive or operate machinery?

A: Official precautions highlight the risk of low blood sugar ( hypoglycemia) from the sulfonylurea component. Patients should be informed about the symptoms of hypoglycemia, as it can affect concentration and the ability to operate machinery or drive safely.

Q: Is there a difference in how the immediate-release and extended-release versions of Orabet work?

A: Regulatory documents specify that the two formulations are used differently: immediate-release is typically taken two or three times a day, while extended-release is typically taken once daily. This difference in dosing frequency indicates they are formulated to control blood sugar over different durations of time.

Q: Are there any herbal supplements or vitamins known to interact with Orabet?

A: Regulatory documentation warns that herbal products may interact with the sulfonylurea component of the drug. The interaction is a factor that may influence the recommended dosage.

Q: Can Orabet be used by people with a history of liver disease?

A: The drug is generally contraindicated (not allowed) in patients with impaired hepatic (liver) function or liver disease, particularly due to the sulfonylurea component. Liver impairment also increases the potential risk of lactic acidosis associated with the Metformin component.

Q: What are the general guidelines for using Orabet around surgery?

A: Official procedural requirements state that the drug requires temporary discontinuation prior to, or at the time of, any elective surgical procedure that involves certain types of anesthesia (general, spinal, or peridural). It may be restarted once kidney function is confirmed as normal.

Q: Can Orabet be taken by people who are breastfeeding?

A: The sulfonylurea component is generally contraindicated during breastfeeding. The drug is known to appear in breast milk, and official information notes there is a theoretical risk of causing low blood sugar ( hypoglycemia) in the nursing infant.

Q: Does Orabet have a risk of allergic reaction?

A: Yes, official labeling notes that the drug is contraindicated in patients with known hypersensitivity or allergy to the drug or other sulfonylureas. Hypersensitivity reactions are also listed among the potential adverse reactions.

Q: Is Orabet effective for people who have Type 1 diabetes?

A: Official regulatory documents indicate that Orabet is intended for Type 2 diabetes. The sulfonylurea component is generally contraindicated as sole therapy for patients with Type 1 diabetes ( insulin-dependent diabetes mellitus).

Q: Is the potential for stomach side effects worse with the higher doses of Orabet?

A: Official regulatory guidelines instruct that dose increases ( titration) should be made gradually to reduce the risk of gastrointestinal side effects. This process indicates that the potential for these side effects is related to dose level.

Q: Is Orabet safe for people who have a history of stroke or heart attack?

A: Official warnings note a special risk of increased cardiovascular mortality associated with the sulfonylurea component of the drug. Regulatory information notes that specific considerations may apply to patients with existing heart conditions.

Q: What information is available about Orabet and uncontrolled blood sugar?

A: Regulatory documents note that if a patient, even one previously stable, experiences physical stress such as a severe infection, trauma, or fever, a loss of blood sugar control may occur. In such cases, the drug may be temporarily discontinued and insulin administered.

Q: What are the general contraindications for Orabet described in official information?

A: General official contraindications include a known allergy ( hypersensitivity) to the drug, diabetic ketoacidosis, Type 1 diabetes (as sole therapy), pregnancy, and severe renal (kidney) or hepatic (liver) impairment.

How should Orabet be stored and disposed of?

How to Store and Dispose of Orabet?

Orabet must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The medication must be protected from light and kept away from excess heat and moisture, such as the bathroom. To maintain its integrity, it should be stored in its original, tightly closed container.

Disposal Instructions

For disposal, the preferred method is utilizing an authorized drug take-back program. If a take-back option is not available, expired or unused Orabet may be discarded in the household trash. This procedure requires tablets to be mixed with an undesirable substance (e.g., used coffee grounds or cat litter), sealed in a container, and then placed in the trash. The medication must be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Orabet found in:

A-Z Index: